Home LiteratureArticle Details
PMID: 7516275 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model.

Hart DA, Whidden P, Green F, Henkin J, Woods DE

Abstract

Pulmonary fibrosis was induced in male Sprague-Dawley rats by intratracheal instillation of bleomycin. By 30 d post-bleomycin, the lungs exhibited elevated interstitial collagen levels. Thirty d after exposure to bleomycin, animals were further treated by intratracheal administration of phosphate-buffered saline (PBS) or 12,500 units of recombinant human urokinase (rh-UK). Three days later, the animals were sacrificed and the lungs fixed, sectioned, and assessed for fibrosis. The presence of interstitial collagen was quantitated using a BioQuant Image Analysis System (R and M Biometrics, Inc., Nashville, TN). Urokinase treatment of animals with established pulmonary fibrosis induced by exposure to 0.5 units of bleomycin was found to diminish the collagen content of lungs to near control levels by 3 d post-UK treatment. By 36 d post-UK treatment (66 d post-bleomycin), values for interstitial collagen were again partially elevated, indicating that UK treatment interfered with established fibrosis but did not stop the bleomycin-mediated process. However, the extent of fibrosis was less than that observed in lungs from non-UK treated animals 66 d post-bleomycin. UK treatment initiated 63 d post-bleomycin exposure again revealed a decline in the extent of fibrosis, but the values did not return to baseline levels. A repeat of the short-term experiment with a higher dose of bleomycin (0.85 units) again revealed that UK treatment was effective in diminishing the extent of fibrosis from 22% to 12% collagen. These results indicate that exogenous UK may be an effective therapeutic modality in the treatment of pulmonary fibrosis induced by some stimuli or developing in association with diseases such as scleroderma.

MeSH Terms
Animals Bleomycin/administration & dosage Collagen/metabolism Dose-Response Relationship, Drug Humans Lung/metabolism,pathology Male Pulmonary Fibrosis/chemically induced,drug therapy,metabolism Rats Rats, Sprague-Dawley Recombinant Proteins/therapeutic use Urokinase-Type Plasminogen Activator/therapeutic use
Chemicals
Recombinant Proteins Bleomycin Collagen Urokinase-Type Plasminogen Activator
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Hart D A
Department of Microbiology and Infectious Diseases, University of Calgary Health Sciences Centre, Alberta.
Whidden P
Green F
Henkin J
Woods D E
Article Info
Journal
Clinical and investigative medicine. Medecine clinique et experimentale
Abbr.
Clin Invest Med
ISSN
0147-958X
Published
1994-04-00
Pages
69-76
Language
English
Region
Canada
NLM ID
7804071
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]